Efruxifermin in non-alcoholic steatohepatitis

Sara Mahgoub¹, Philip N Newsome²

Affiliations

¹ National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
² National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: p.n.newsome@bham.ac.uk.

PMID: 37802089
DOI: 10.1016/S2468-1253(23)00285-6

Comment

Efruxifermin in non-alcoholic steatohepatitis

Sara Mahgoub et al. Lancet Gastroenterol Hepatol. 2023 Dec.

. 2023 Dec;8(12):1058-1059.

doi: 10.1016/S2468-1253(23)00285-6. Epub 2023 Oct 3.

Authors

Sara Mahgoub¹, Philip N Newsome²

Affiliations

¹ National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
² National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK; Centre for Liver and Gastrointestinal Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: p.n.newsome@bham.ac.uk.

PMID: 37802089
DOI: 10.1016/S2468-1253(23)00285-6

Erratum in

Correction to Lancet Gastroenterol Hepatol 2023; 8: 1058-59.
[No authors listed] [No authors listed] Lancet Gastroenterol Hepatol. 2023 Dec;8(12):e9. doi: 10.1016/S2468-1253(23)00359-X. Lancet Gastroenterol Hepatol. 2023. PMID: 37951240 No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

PNN discloses the following financial relationships on behalf of the University of Birmingham with a commercial interest: grant or research support from Novo Nordisk and consulting fees from Astra Zeneca, Boehringer Ingelheim, BMS, Gilead, GSK, Intercept, Madrigal, Novo Nordisk, Pfizer and Sun Pharma. SM declares no competing interests.

Comment on

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, Gogia S, Sheikh MY, Behling C, Bedossa P, Shao L, Chan D, Fong E, de Temple B, Shringarpure R, Tillman EJ, Rolph T, Cheng A, Yale K; HARMONY Study Group. Harrison SA, et al. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1080-1093. doi: 10.1016/S2468-1253(23)00272-8. Epub 2023 Oct 3. Lancet Gastroenterol Hepatol. 2023. PMID: 37802088 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efruxifermin in non-alcoholic steatohepatitis

Affiliations

Efruxifermin in non-alcoholic steatohepatitis

Authors

Affiliations

Erratum in

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical